Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Top-Tier Pharma Companies, Mid-Sized Peers Mixed on Special PMP Step: New Year Confab
January 10, 2023
- Leqembi Likely to Hit Peak Sales after 2030, US$26,500 Price Matches Value: Eisai CEO
January 10, 2023
- Lecanemab Nabs Accelerated Approval in US, Set to Hit Market Late January
January 10, 2023
- Takeda’s TAK-755 Shows Promising PIII Interim Data for Ultra-Rare Blood Clotting Disorder
January 10, 2023
- Kaken Earns Japan Rights to CAH Med, Poised to Boost Rare Disease Biz
January 10, 2023
- Nippon Shinyaku Launches Open Innovation-Driven Drug Discovery Hub in US
January 10, 2023
- Fujifilm US Subsidiary Licenses iPSC Platform to Novo
January 10, 2023
- US Federal Circuit Nixes Lexiscan Patent Infringement, Astellas to File Appeal
January 6, 2023
- Dayvigo Tops HP Ranking, Twymeeg Most Promoted in GP Market 5 Months Running in November: Intage
January 6, 2023
- Shionogi Reports 2 Serious Side Effect Cases in Xocova Update
January 6, 2023
- Xocova Filed for Conditional Approval in South Korea
January 6, 2023
- Enhertu’s Application for NSCLC Use Accepted in Europe: Daiichi Sankyo
January 6, 2023
- Moderna Snags Tokyo Upstart in Its 1st M&A Deal, Staff to Join Japan Unit
January 6, 2023
- Creditors Approve Nichi-Iko’s Turnaround Scheme, Grants Debt Waiver of 98.5 Billion Yen
January 5, 2023
- Steve Sugino Becomes New CEO of BMS Japan
January 5, 2023
- Japan Likely to See Generic Listing for Azilva, Zytiga in 2023; Xarelto AG Rivals Too
January 5, 2023
- Sun Pharma Japan Gearing Up Sales of Flagship Dermatology Med Ilumya: President
December 28, 2022
- RaQualia, Veritas Seal mRNA Drug Discovery Collaboration
December 28, 2022
- PeptiDream, Lilly Ink Collab with Up to US$1.2 Billion in Milestones
December 27, 2022
- Estimated 4,640 Patients Took Xocova by Dec. 18: Shionogi
December 27, 2022
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…